Background. Detection of glioma with MRI contrast agent is limited to cases in which the blood-brain barrier (BBB) is compromised as contrast agents cannot cross the BBB. Thus, an early-stage infiltrating tumor is not detectable. Interleukin-13 receptor alpha 2 (IL-13Ra2), which has been shown to be overexpressed in glioma, can be used as a target moiety. We hypothesized that liposomes conjugated with IL-13 and encapsulating MRI contrast agent are capable of passing through an intact BBB and producing MRI contrast with greater sensitivity.
1
One of the major reasons for such a dismal outcome is lack of a sensitive tool for detecting infiltrating tumors at an early stage when treatment is more effective. Currently available MRI contrast agents for the detection of brain tumors, such as gadolinium diethylenetriaminepentacetate (Gd-DTPA, Magnevist), are nonspecific and only detect tumor masses that have significantly damaged the blood-brain barrier (BBB).
2 Malignant brain tumors in their early stage, especially glioblastoma multiforme (GBM), infiltrate aggressively into the brain tissues, where they cannot be enhanced by the MRI contrast agent in most cases because the BBB has not been significantly damaged. Moreover, the borders indicated by contrast-enhanced MRI do not necessarily reflect all of the tumor and normal tissue boundaries. GBM generally recurs because of the proliferation of undetected infiltrating tumor cells or the chemoresistant glioma stem cells that migrate from the primary tumor sites. The current clinical image modalities (ie, MRI, PET, and CT) can only resolve a tumor size of ≥2 mm. 3, 4 The effectiveness of current treatment and development of new therapies is thus critically limited by the difficulties in detection of these infiltrating tumors at an early stage distal to the primary tumor sites.
The BBB consists of astrocytes, basement membrane, and endothelial cells characterized by intercellular tight junctions that prevent 98% of small molecules and all large molecules from entering the brain. In addition, lipid-mediated molecules are restricted to diffuse in and out of the BBB if they are .400 Da and form .8 hydrogen bonds. 5, 6 The ability to penetrate the BBB has been a challenge for developing diagnostic and therapeutic agents for tumors in the CNS. 7 -9 Liposomes have been shown to be a promising drug delivery vehicle to the CNS because of their ability to encapsulate drugs and conjugate antibodies or ligands on their surface. 10 -12 Drug transport to the brain with targeted liposomes has shown improved efficacy for treating tumor animal models, indicating that liposomes have the ability to pass through the BBB. 13 However, it has not been directly demonstrated in vivo that liposomes can cross an intact BBB. Previous studies demonstrated that liposomes could deliver Gd-DTPA into hepatoma and enhance the MRI contrast. 14 -17 For the purpose of detecting tumors in the brain with MRI, however, a contrast agent having the ability to pass through the BBB could present a potential problem because it would enhance all brain tissue and thus lose its ability to differentially highlight the tumor tissues. Therefore, the liposome carrying an MRI contrast agent must be able to specifically target brain tumor tissues in order to highlight them. Fortunately, it has been demonstrated that glioma tumor cells overexpress interleukin-13 receptors alpha 2 (IL-13Ra2), while cells in normal brain tissues and other organs only express insignificant amounts of IL-13Ra2. 18, 19 Based on Debinski et al, 100% of high-grade gliomas (grade III) and GBMs, 60% of oligodendrogliomas, 50% of gliosarcomas, and 24% of low-grade gliomas overexpress IL-13Ra2. 20 -22 According to Sikorska et al, 100% of high-grade astrocytomas overexpress IL-13Ra2. 23 In a recent review article, IL-13Ra2 was expressed in 58% of adult and 83% of pediatric brain tumors. 24 The overexpression of IL-13Ra2 on malignant glioma cells with 30 000 IL-13 binding sites per cell has created an opportunity for using liposomes to target glioma cells. 25 Utilizing this property, Madhankumar et al applied IL-13-liposomes (IL-13-Lip) containing an anticancer drug (doxorubicin) that specifically targeted the GBM and led to a more effective therapeutic outcome than utilizing doxorubicin alone. 26, 27 Debinski et al also found that IL-13Ra2-targeted therapy preferentially targeted the stem-like cell population, which possibly indicated decreased tumorigenicity in vivo. 28 IL-13 was also used as a brain tumor target for imaging. 22, 26 Chittiboina et al applied antibody interleukin-13 -Pseudomonas exotoxin with the co-infusion of Gd-DTPA. 29 Based on these studies, we hypothesized that encapsulation of Magnevist into liposomes conjugated with IL-13 would generate a novel contrast agent that could cross the intact BBB and target glioma cells specifically, such that early stage glioma could be detected. To test our hypothesis, glioma U251 and glioma stem cell lines isolated from GBM patients and athymic nude mice were selected as our in-vitro and in-vivo models, respectively. 21, 30, 31 This report presents the development and characterization of IL-13-Lip-Gd-DTPA and provides in-vivo evidence of its ability to cross an intact BBB in normal mouse brain and its ability to target infiltrating glioma tissues in the mouse tumor model.
Materials and Methods
All animal experimental procedures were carried out in accordance with institutional guidelines and approved by the Animal Care and Use Committee of the Pennsylvania State University College of Medicine. (2000) Maleimide) in the mole ratio of 10:5:5:0.5 was dissolved in a mixture of methanol/chloroform 1:1 (volume to volume ratio). Subsequently, the organic solvent was evaporated using a rotator vapor to receive a film. With the vibration of ultrasound, the film was reconstituted in a saturated solution mixed by Gd-DTPA with poly-L-lysine (Sigma) (ratio, 8 mL:5 mg) to formulate multilamellar vesicles. The multilamellar vesicles were extruded through the polycarbonate membranes with 4 passes through at 200 and 100 nm sequentially. Then, Lip-Gd-DTPA was conjugated with human IL-13 protein by incubating the IL-13 with Lip-Gd-DTPA overnight at 48C. 26 To remove the free IL-13 protein, the sample with IL-13-Lip-Gd-DTPA was passed through a Sepharose CL-2B column, and then IL-13-Lip-Gd-DTPA was exhaustively dialyzed overnight against PBS at 48C and concentrated for the final product.
The size distribution of IL-13-Lip-Gd-DTPA was determined by measuring the polydispersity index with light-scattering analysis using Malvern Zetasizer (Ver. 3.16; Brookhaven Instruments). The morphology of IL-13-Lip-Gd-DTPA was examined with a negative stain transmission electron microscopy (TEM) (JEOL 1400 TEM at 120 kV). To evaluate the loading efficiency of Gd in IL-13-Lip, IL-13-Lip-Gd-DTPA was digested in 20% nitric acid overnight at 1008C, and the concentration of Gd was then quantified using inductively by coupled plasma-atomic emission spectroscopy (ICP-AES) with a Perkin Elmer spectrometer. Consistent with previous stability studies, 32 IL-13-Lip-Gd-DTPA in phosphate-buffered saline is stable at 48C for at least one month based on its size distribution and MRI relaxivity measurements, which were performed as a quality assurance routine before all in-vivo experiments.
IL-13-Lip-Gd-DTPA Crossing the Blood-brain Barrier in an in-vitro Model
The ability of IL-13-Lip-Gd-DTPA to cross the BBB was evaluated using an established bichamber in-vitro BBB model, as previously described; 26 details can be found in the Supplementary Materials.
IL-13-Lip-Gd -DTPA Crossing the Blood-brain Barrier in a Normal Mouse in-vivo Model MRI studies were carried out to evaluate the ability of IL-13-Lip-Gd-DTPA to penetrate an intact BBB in vivo with normal mice. Two groups of animals (n ¼ 3) were anesthetized with 2% isoflurane/oxygen and subsequently injected through the tail vein with either free Magnevist or IL-13-Lip-Gd-DTPA. The amount of injection was normalized to 736 mg of gadolinium. Axial T1-weighted images were acquired on a 7.0 T MRI system with 540/11 ms TR/TE, 8 
Glioma Mouse Model and Histological Chemistry
For testing IL-13-Lip-Gd-DTPA as a targeted contrast agent for glioma, the intracranial tumor model was prepared as previously described. 26, 28 The tumor formation and volume were monitored weekly with Magnevist-enhanced T1-weighted MRI starting at 2 weeks post tumor induction. When a tumor reached a size of 5-10 mm in diameter, the mice were imaged with the T1-weighted scan after injection of Magnevist as a control and FITC-labeled liposome (IL-13-Lip(FITC)-Gd-DTPA). Then, the mice were euthanized at 2 hours post injection of IL-13-Lip(FITC)-Gd-DTPA, and the brains were harvested and frozen immediately at 2208C. The brain tissue was sectioned at a 12 mm thickness at 2208C and mounted on slides. The selected neighboring brain tissue slides were stained separately with hematoxylin and eosin (H&E) for tumor tissue identification, or DAPI for FITC-labeled liposomes accumulation in the glioma or with immunostaining for observation of IL-13Ra2 differential expressions between glioma and adjacent normal tissue following the standard protocol (See details in Supplementary Materials).
A number of other tests were performed. IL-13-Lip-Gd-DTPA uptake, cytoxicity by GSC T3691 and U251, and in-vivo toxicity in mouse model were conducted. Immunoblotting analyses were performed for conjugation of IL-13 with liposomes and expression of IL-13Ra2 in glioma and glioma stem cells. An MRI study was carried out for each batch of IL-13-Lip-Gd-DTPA. The experimental procedures of the above-mentioned studies are described in detail in the Supplemental Material in the sections of animal models and cell cultures, uptake of IL-13-Lip-Gd-DTPA by GSC T3691 and U251, cytotoxicity of IL-13-Lip-Gd-DTPA, in-vivo toxicity studies, immunoblotting analysis of the conjugation of IL-13 with liposomes, immunoblotting analysis for expression of IL-13Ra2 in glioma and glioma stem cells, immunohistochemistry in normal mouse model, and MRI study of IL-13-Lip-Gd-DTPA.
Results

Characterization of IL-13-Lip-Gd-DTPA
The average size of IL-13-Lip-Gd-DTPA was 137+43 nm, which was consistent for four 48C different batches. 
IL-13-Lip-Gd-DTPA Toxicity Assessment
The cytotoxicity of the liposomes was not observed in either the in-vitro MTS assay or the in-vivo serum chemistry data. As shown in Fig. 2A and B, U251 and T3691 cell exposure to Gd concentrations in liposomes from 15 mg/mL-60 mg/mL did not produce a significant difference in cell cytotoxicity when compared with the controls using MTS assays. In addition, the blood serum chemistry study between the control (injection of Magnevist) and the injection of IL-13-Lip-Gd-DTPA into mice did not show any significant toxicity in terms of blood urea nitrogen mg/dL, total bilirubin mg/dL, creatinine mg/dL (Fig. 2C) , AST U/L, and ALT U/L (Fig. 2D) . However, alkaline phosphatase U/L, appeared to be lowered in the mice treated with liposomes, which was likely caused by the minor perturbations of nutritional uptake. 33 IL-13-Lip-Gd-DTPA Uptake Figure 3 shows confocal microscopy images captured after exposure of FITC labelled IL-13-Lip-Gd-DTPA to the cell cultures. The FITC green color in Fig. 3A -C indicated the presence of liposomes in the cytosol of glioma U251, U87, and T3691 cells, respectively, thus demonstrating the uptake of IL-13-Lip-Gd-DTPA by all 3 cell lines.
IL-13-Lip-Gd-DTPA Crossing BBB in-vitro Model Figure 4 shows the Gd concentration transported from the apical to the basal chamber of the BBB in-vitro model at 2, 4, and 24 hours. At 2 hours, the Gd concentration of free Gd-DTPA and IL-13-Lip-Gd-DTPA did not show a marked difference. But at 4 hours, the Gd concentration from the IL-13-Lip-Gd-DTPA was 6000 mg/L, which is 3-fold greater than that from free Gd-DTPA. This difference in Gd concentration in the basal chamber suggested that IL-13-Lip-Gd-DTPA facilitated Gd crossing the BBB in the in-vitro model. Rhodamine-labeled dextran, 
IL-13-Lip-Gd-DTPA Crossing BBB in Normal Mice
The encapsulation of contrast agent into the liposomes made it possible to assess the ability of liposomes to cross the intact BBB in vivo by MRI by injection of IL-13-Lip-Gd-DTPA into normal mice. For histological analysis, the liposomes used in this study were labeled with FITC. As illustrated in Fig. 5A , the signal changes in the pituitary gland (blue trapezoid) and the brain tissues (red ellipse) were measured on the T1-weighted MRI of the same slice post injection of either Magnevist or IL-13-Lip-Gd-DTPA. The signal changes of the pituitary gland were used to make certain that the contrast agents IL-13-Lip-Gd-DTPA (Fig. 5A-a-V) or Magnevist (Fig. 5A-c-V) entered the blood stream. Since the pituitary gland does not have a BBB, the signal increased for about a 2 hour period in the pituitary gland for both cases, indicating that the liposomes encapsulated with Gd-DTPA were capable of inducing similar MRI contrast as Magnevist. Accordingly, the signal change in brain parenchyma provided an indication whether IL-13-Lip-Gd-DTPA or Magnevist crossed the intact BBB. As shown in the time courses in Fig. 5A-a-B , the signal of brain parenchyma followed similar temporal characteristics as that of the pituitary gland, with an increase up to 15% at 30 minutes post injection of IL-13-Lip-Gd-DTPA. As anticipated with injection of Magnevist, the signal from brain parenchyma shown in Fig. 5A -c-B remained unchanged because the Magnevist was blocked by the intact BBB. These data provided the first direct in-vivo evidence that IL-13-Lip-Gd-DTPA penetrated an intact BBB and entered the brain parenchyma of a living mouse.
To validate the in-vivo findings, histology was performed on the animals. Fig. 5B shows confocal microscopy images from a brain tissue section of a mouse after injection of FITC labeled IL-13-Lip-Gd-DTPA Fig. 5B-(a-f) and a control Fig. 5B-(g-i) , respectively. The confocal images confirmed the in-vivo results with a widespread FITC distribution in the brain tissue compared with the complete absence of FITC in brain tissues without injection of IL-13-Lip(FITC)-Gd-DTPA. It is also important to note that the FITC-labeled liposomes were sparsely distributed. The magnified image (63X) in Fig. 5B -e indicated that the liposomes remaining in the brain were intracellular. The confocal microscopy images in Fig. 5C showed DAPI, FITC-liposomes, Ab GFAP-rhodamines, and co-localization of IL-13-Lip(FITC)-Gd-DTPA in a, b, c and d, respectively, which also confirmed that IL-13-Lip(FITC)-Gd-DTPA entered the brain tissue and co-localized with one of the astrocytes markers, GFAP.
Detection of Glioma by IL-13-Lip-Gd-DTPA
To further test the functionality of IL-13-Lip-Gd-DTPA as an MRI contrast agent for the detection of glioma, Fig. 6A shows an example of T1-weighted MR images acquired at the identical location from the same mouse with an intracranial tumor after receiving the Magnevist (Fig. 6A-a,-c) and IL-13-Lip-Gd-DTPA injections 24 hours apart (Fig. 6A-b, -d) . As seen in the MR images from the primary tumor site, IL-13-Lip-Gd-DTPA produced similar contrast as Magnevist (white arrows) and delineated the tumor masses. However, there were additional small tumor masses that could be identified by IL-13-Lip-Gd-DTPA proximal to the primary tumor site (red arrows in Fig. 6A-b) . Similarly, as indicated in Fig. 6A-d , IL-13-Lip-Gd-DTPA detected several additional tumor masses, which Magnevist failed to delineate, in the brain slice about 2 mm posterior to the primary site in Fig. 6A-c . This finding was confirmed by histology of the same tissue slice shown in Fig. 6B . As indicated in the zoomed-in image of H&E stain in Fig. 6B -e, f, a tumor mass (dark purple color) was positively identified in the same location as in the MRI image in Fig. 6A-d . In this tumor site, high accumulation of FITC-labeled liposomes were observed in Fig. 6B-g, indicating the effective targeting of the liposome. Accordingly, the confocal immunohistochemistry image in Fig. 6B -h demonstrated IL-13Ra2 differential expressions in glioma and the adjacent normal tissues.
Discussion
We presented novel in-vivo data demonstrating that we have developed a nanotechnology platform capable of passing through the BBB and delivering MRI contrast directly to brain tumors. The BBB is the major obstacle in delivering chemotherapeutic agents to the brain. Current techniques for enhancing penetration of the BBB can be classified into 2 categories: (i) bypassing the BBB through convection-enhanced delivery 34, 35 and focused ultrasound-mediated delivery. 36, 37 These kinds of approaches can be effective for delivering drugs to Liu et al.: MRI contrast agent for targeting glioma known cancer sites, but convection-enhanced delivery is invasive, and ultrasound-mediated delivery requires the stratum corneum to be intact and is time-consuming to administer, all of which offer little help for cancer detection. (ii) BBB nondisruptive approaches such as receptor-mediated delivery with liposomes or other delivery vehicles. Surface-pegylated liposomes are often used for this purpose because pegylation improves liposome stability in the blood stream and subsequently enhances ability to deliver agents. 38, 39 Such liposomes, especially those of a smaller size (eg, 50-200 nm), are believed to be able to extravasate the relatively permeable vasculature of tumors and promote efficient accumulation in the tumor interstitium (a phenomenon known as the enhanced permeability and retention (EPR) effect). However, there had been no direct experimental evidence and method to assess such ability in vivo. By encapsulating MRI contrast agent into our liposome, the penetration of an intact BBB by the liposome is clearly indicated in vivo in normal mice. Furthermore, our liposomal approach provides a possibility for developing our nanotechnology into a theranostic delivery system by combining chemotherapeutic agents or molecular targets with the MRI contrast agent.
Previous in-vivo data demonstrating that the liposome was capable of penetrating the BBB were based on indirect measurements showing higher drug efficacy with the liposome in an intracranial tumor model. 27 Since the BBBs of the intracranial tumor models are known to be compromised, the data obtained with tumor models are deemed to be inconclusive on the ability of the liposome to cross the BBB. In our data shown in Fig. 5A -a, the MRI signal was enhanced up to 15% in the brain tissue with IL-13-Lip-Gd-DTPA in normal mice without a tumor. The MRI signal enhancement in the brain followed the same temporal characteristics as the pituitary gland, which served as an intracranial reference outside the BBB. In addition, the in-vivo data were validated histologically from the same group of mice by fluorescently labeling the FITC. A certain amount of FITC was found to be sparsely distributed in the brain tissues in all animals treated with FITC-labeled liposome as shown in Fig. 5B-b . Co-localization of FITC-labeled IL-13-Lip(FITC)-Gd-DTPA with astrocyte marker GFAP is illustrated in Fig. 5C -b,-c and Fig. 5C-d demonstrates that IL-13-Lip(FITC)-Gd-DTPA entering the normal brain tissue. Taken together, our experimental results provided concrete evidence that IL-13-liposome facilitates Gd-DTPA passing through an uncompromised BBB.
Comparing the time course from in-vitro model, our in-vivo data indicated that the in-vitro model may not be suitable for the study of the kinetics of this process as it uses only gravitational force in thermal equilibrium to increase interactions with the endothelial cell layer, while the blood flow, blood pressure, vessel geometry, and morphologies for the in-vivo condition are all involved in the liposomal transport into the BBB. In future studies, it will be necessary to acquire quantitative data on IL-13-Lip-mediated transport of gadolinium through the BBB in order to understand the underlying mechanism and establish a kinetic model.
The average size and size distribution of the liposomes are important factors for their ability to cross the BBB and for systematic cytotoxicity. 40 Thus, the size distribution and the lipid composition of the liposomes have been previously studied intensively. 14 -16,41 The average size of our liposome was 130 nm distributed within a narrow range of 40-300 nm (Fig. 1) . Our liposome was composed of polyethylene glycol (PEG), which permitted the liposome to escape the immune system responses and increase its circulating time. 42 With this formulation, no detectable cytotoxicity was observed in either cell culture or serum blood chemistry. As we discussed in the introduction, our liposome facilitates the MRI contrast agent passing through the BBB, but it is not sufficient if the contrast agent is not differentially accumulated in the tumor. As shown in the brain image of a normal mouse in Fig. 5A -a, the MRI signal from the brain parenchyma increased uniformly at the same time after injection of our IL-13-Lip-Gd-DTPA and yielded no visible image contrast change. We knew that the measurements of brain Gd-DTPA tissue concentrations using MRI and ICP-AES demonstrated a high degree of coincidence. 43 Thus, in order to highlight tumors, a contrast agent must be able to preferentially target the tissue of interest. As shown by the comparison in Fig. 6A-a and Ab, IL-13-Lip-Gd-DTPA generated similar contrast as Magnevist. In this case, both contrast agents could perfuse into the brain tissue near the tumor site where the BBB was compromised. A closer look at the images in Fig. 6A-b and -d reveals several additional enhanced areas surrounding the primary tumor site. The areas enhanced only by IL-13-Lip-Gd-DTPA were infiltrating tumors. The advantage of our targeted contrast agent is undoubtedly demonstrated in Fig. 6A-b and A-d, where the tumor masses are small, distal to the primary site, and can be identified only with our liposomal contrast agent. As seen in Fig. 6B , the infiltrating tumor identified by our contrast agent presented the typical histological characteristics of GBM. In this case, the tumor masses had not caused significant damage to the BBB such that it could not be detected with Magnevist Fig. 6A-c . The large amount of FITC found in this tumor site in Fig. 6B -g is additional confirmation that the contrast in the tumor produced by our agent was a result of its ability to pass through the BBB and preferentially deliver the MRI contrast agent to the glioma tissues. In addition, those tumor masses enhanced only by IL-13-Lip-Gd-DTPA preserved signal enhancement 24 hours post injection. The sustained signal enhancement by our targeted liposome in the infiltrating tumor sites behind the intact BBB was possible only if the contrast agent was in the intracellular space. This is consistent with the previous studies. In these studies, the targeting ability for glioma was determined indirectly by assessing its efficacy in inhibiting the tumor growth. 26 
Conclusion
We have developed and characterized IL-13-Lip-Gd-DTPA. We demonstrated in vivo that our agent is capable of delivering Gd-DTPA through the intact BBB in normal mice and preferentially targeting the glioma tissues in an intracranial mouse model. The in-vivo data were validated with postmortem histology from the same animal. The significance of this research is addressing an unmet need in diagnosis and treatment of glioma by developing a novel MRI contrast agent that directly targets specific receptors on the neoplastic cells, thereby enhancing uptake of the MRI contrast locally in the tumor tissues with greater specificity and sensitivity. Our approach provides feasibility for future development of a theranostic agent targeting glioma.
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